Market Overview - Stock futures are modestly higher following the December nonfarm payrolls report and ahead of a Supreme Court decision on President Trump's tariff policy [1] - Major indexes have shown resilience early in 2026 after a strong finish to 2025, but gains have faced headwinds due to cooling tech momentum and uncertainty around labor data affecting Federal Reserve policy expectations [1] Sector Performance - Defensive sectors such as energy and mining have demonstrated relative strength, while value-oriented and cyclical areas are gaining attention amid market rotation [2] - Safe-haven assets like gold have seen increased demand as risk sentiment fluctuates [2] Pre-Market Trading - In pre-market trading, S&P 500 futures rose by 0.33%, Nasdaq futures increased by 0.42%, and Dow futures were up by 0.32% [2] Company Movements - Oklo (OKLO) is up 18% after announcing an agreement with Meta Platforms (META) to develop a 1.2 GW power campus in Pike County, Ohio [5] - Vistra (VST) increased by 17% after entering into 20-year purchase power agreements to provide over 2,600 megawatts of zero-carbon energy from three nuclear plants for Meta's operations [5] - Intel (INTC) rose by 2% following President Trump's positive remarks about a meeting with CEO Lip-Bu Tan [5] - Offerpad Solutions (OPAD) surged by 48%, LoanDepot (LDI) increased by 16%, Opendoor Technologies (OPEN) rose by 11%, Rocket Companies (RKT) was up by 6%, and UWM Holdings (UWMC) also increased by 6% [5] - Conversely, Aquestive Therapeutics (AQST) fell by 37% after the FDA identified deficiencies in its Anaphylm NDA, while AXT Inc. (AXTI) dropped by 14% after cutting its Q4 revenue outlook [5]

Market Overview - U.S. equities ended the first full trading week of 2026 positively, with major benchmarks like the S&P 500 and Dow Jones Industrial Average reaching new record highs, influenced by geopolitical events and a mixed December jobs report [2] - Investors shifted focus from mega-cap technology stocks to cyclical sectors, particularly energy and defense, following a significant U.S. military operation in Venezuela and expectations of increased crude supply [2][3] Sector Performance - Energy and defense stocks led the market gains, with oil-related equities rising due to optimism about Venezuela's potential to supply crude oil to U.S. markets, while defense contractors benefited from plans for a larger Pentagon budget in 2027 [3] - Smaller defense contractors outperformed the broader market, indicating a shift in market leadership influenced by geopolitical factors [3] Economic Data - The December jobs report indicated slower than expected payroll growth but a lower unemployment rate, alleviating some investor concerns regarding labor market stress [4] - Mixed sentiments around inflation and labor conditions suggested that the Federal Reserve may maintain steady interest rates in the near term [4] Notable Stock Movements - Chevron Corp. (NYSE:CVX) shares rose approximately 5.8% following U.S. military actions in Venezuela, which boosted investor optimism about accessing Venezuelan oil resources [5] - Palantir Technologies Inc. (NASDAQ:PLTR) stock gained momentum amid speculation of its involvement in U.S. military operations in Venezuela, attracting attention from investors and analysts [6] - Nuclear energy stocks, including Centrus Energy Corp. (NYSE:LEU) and Energy Fuels Inc. (NYSE:UUUU), rallied after the Trump administration announced expanded federal support for domestic nuclear infrastructure, enhancing long-term demand prospects [7] Bearish Trends - Real estate and housing-linked stocks experienced significant sell-offs after President Trump announced plans to limit large institutional investors from purchasing single-family homes, impacting major players like Blackstone Inc. (NYSE:BX) and Invitation Homes Inc. (NASDAQ:INVH) [9] - U.S. defense stocks fell sharply after Trump ordered major defense contractors to halt dividends and share buybacks until they increased investments in production, affecting companies like Lockheed Martin Corp. (NYSE:LMT) and Northrop Grumman Corp. (NYSE:NOC) [10] - Aquestive Therapeutics Inc. (NASDAQ:AQST) shares dropped after the FDA flagged issues with its allergy drug application, raising concerns about potential delays in the approval process [11]

ATLANTA, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) complied with federal securities laws. On January 9, 2026, Aquestive disclosed that it received a notice from the FDA that it “had identified deficiencies in the New Drug Application (NDA) submitted by the Company for its product candidate, Anaphylm™ (epinephrine) Sublingual Film, for the treatment of severe allergic reactions, including anaphyla ...

ARS Pharmaceuticals Inc. (NASDAQ:SPRY) stock rose Friday in reaction to a negative update for its rival Aquestive Therapeutics Inc. (NASDAQ:AQST).The U.S. Food and Drug Administration (FDA) identified deficiencies in Aquestive’s Anaphylm’s New Drug Application (NDA) that preclude discussion of labeling and post-marketing commitments at this time.The FDA stated that the notification does not reflect a final decision on the pending application, and the FDA’s review remains ongoing.In an investor note, William ...

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 150 points on Friday.The Dow traded up 0.38% to 49,453.05 while the NASDAQ climbed 0.66% to 23,635.11. The S&P 500 also rose, gaining, 0.48% to 6,954.85.Check This Out: Delta Air Lines Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings CallLeading and Lagging SectorsUtilities shares gained by 1.5% on Friday.In trading on Friday, health care stocks dipped by 0.5%.Top HeadlineThe Univ ...

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 150 points on Friday.The Dow traded up 0.38% to 49,453.05 while the NASDAQ climbed 0.66% to 23,635.11. The S&P 500 also rose, gaining, 0.48% to 6,954.85.Check This Out: Delta Air Lines Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings CallLeading and Lagging SectorsUtilities shares gained by 1.5% on Friday.In trading on Friday, health care stocks dipped by 0.5%.Top HeadlineThe Univ ...

To learn more about the Aquestive Therapeutics investigation, go to www.faruqilaw.com/AQST or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular ca ...

Aquestive Therapeutics Inc. (NASDAQ:AQST) stock is trading lower on Friday, with a session volume of 5.68 million compared to the average volume of 2.79 million, as per data from Benzinga Pro.Why Did It Fall?The company on Friday said the U.S. Food and Drug Administration (FDA) has identified deficiencies in Anaphylm’s New Drug Application (NDA) that preclude discussion of labeling and post-marketing commitments at this time.Although the notification did not specify the deficiencies, Aquestive is working to ...

BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Aquestive Therapeutics, Inc. (Nasdaq: AQST) for potential securities law violations. Investors who have lost money in their Aquestive Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/aqst. What is this all about? Shares of Aquestive Therapeutics fell more than 40% on January 9, 2026, after the company disclosed that th ...

Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives confirmation from FDA that Agency’s review of Anaphylm NDA application is ongoing and no final FDA decision has been madeProgresses global regulatory expansion activities in Canada, Europe, and the United Kingdom for AnaphylmUnaudited cash and cash equivalents of approximately $120 million as of December 31, 2025 WARREN, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Aquestiv ...